MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer

Neoplasia (United States)

Volumn 14, Issue 9, 2012, Pages 868-879

  Cekaite, Lina ^a,b   Rantala, Juha K ^c   Bruun, Jarle ^a,b   Guriby, Marianne ^a,b   Ågesen, Trude H ^a,b   Danielsen, Stine A ^a,b   Lind, Guro E ^a,b   Nesbakken, Arild ^b,d   Kallioniemi, Olli ^e,f   Lothe, Ragnhild A ^a,b   Skotheim, Rolf I ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d AKER UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF HELSINKI   (Finland)

^f VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 1; MICRORNA 10B; MICRORNA 126; MICRORNA 15A; MICRORNA 182; MICRORNA 21; MICRORNA 210; MICRORNA 214; MICRORNA 221; MICRORNA 31; MICRORNA 9;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 84866550711     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121094     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D (2011). Global cancer statistics. CA Cancer J Clin 61, 69-90.
2. Dean M (1998). Cancer as a complex developmental disorder-nineteenth Cornelius P. Rhoads Memorial Award Lecture. Cancer Res 58, 5633-5636.
3. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al. (2005). MicroRNA expression profiles classify human cancers. Nature 435, 834-838.
4. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, and Sung JJ (2009). Differential expression of microRNAs in plasma of colorectal cancer patients: a potential marker for colorectal cancer screening. Gut 58, 1375-1381.
5. Wu CW, Ng SS, Dong YJ, Ng SC, Leung WW, Lee CW, Wong YN, Chan FK, Yu J, and Sung JJ (2011). Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut, 739-745.
6. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, et al. (2008). MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299, 425-436.
7. Ruddon R (2007). Cancer Biology. Oxford University Press, New York, NY.
8. Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, Huber LA, Zatloukal K, et al. (2005). Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 7, 545-555.
9. Chekulaeva M and Filipowicz W (2009). Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells. Curr Opin Cell Biol 21, 452-460.
10. Iorio MV and Croce CM (2012). MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4, 143-159.
11. Sarver AL, French AJ, Borralho PM, Thayanithy V, Oberg AL, Silverstein KA, Morlan BW, Riska SM, Boardman LA, Cunningham JM, et al. (2009). Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 9, 401.
12. Berg M, Danielsen SA, Ahlquist T, Merok MA, Ågesen TH, Vatn MH, Mala T, Sjo OH, Bakka A, Moberg I, et al. (2010). DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PloS One 5, e13978.
13. Rantala JK, Makela R, Aaltola AR, Laasola P, Mpindi JP, Nees M, Saviranta P, and Kallioniemi O (2011). A cell spot microarray method for production of high density siRNA transfection microarrays. BMC Genomics 12, 162.
14. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al. (2004). Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5, R80.
15. Ågesen TH, Sveen A, Merok MA, Lind GE, Nesbakken A, Skotheim RI, and Lothe RA (2012). ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut. Epub ahead of print.
16. Sveen A, Ågesen TH, Nesbakken A, Rognum TO, Lothe RA, and Skotheim RI (2011). Transcriptome instability in colorectal cancer identified by exon microarray analyses: associations with splicing factor expression levels and patient survival. Genome Med 3, 32.
17. Fabbri M (2010). miRNAs as molecular biomarkers of cancer. Expert Rev Mol Diagn 10, 435-444.
18. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr, Sjoblom T, Barad O, Bentwich Z, Szafranska AE, Labourier E, et al. (2006). The colorectal microRNAome. Proc Natl Acad Sci USA 103, 3687-3692.
19. Olaru AV, Selaru FM, Mori Y, Vazquez C, David S, Paun B, Cheng Y, Jin Z, Yang J, Agarwal R, et al. (2011). Dynamic changes in the expression of microRNA-31 during inflammatory bowel disease-associated neoplastic transformation. Inflamm Bowel Dis 17, 221-231.
20. Earle JS, Luthra R, Romans A, Abraham R, Ensor J, Yao H, and Hamilton SR (2010). Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J Mol Diagn 12, 433-440.
21. Wang CJ, Stratmann J, Zhou ZG, and Sun XF (2010). Suppression of micro- RNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells. BMC Cancer 10, 616.
22. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R, and Vyzula R (2007). Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 72, 397-402.
23. Wang CJ, Zhou ZG, Wang L, Yang L, Zhou B, Gu J, Chen HY, and Sun XF (2009). Clinicopathological significance of microRNA-31, -143 and -145 expression in colorectal cancer. Dis Markers 26, 27-34.
24. Cottonham CL, Kaneko S, and Xu L (2010). miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem 285, 35293-35302.
25. Chang KH, Miller N, Kheirelseid EA, Lemetre C, Ball GR, Smith MJ, Regan M, McAnena OJ, and Kerin MJ (2011). MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. Int J Colorectal Dis 26, 1415-1422.
26. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC, Brock JE, Richardson AL, and Weinberg RA (2009). A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137, 1032-1046.
27. Creighton CJ, Fountain MD, Yu Z, Nagaraja AK, Zhu H, Khan M, Olokpa E, Zariff A, Gunaratne PH, Matzuk MM, et al. (2010). Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res 70, 1906-1915.
28. Barshack I, Lithwick-Yanai G, Afek A, Rosenblatt K, Tabibian-Keissar H, Zepeniuk M, Cohen L, Dan H, Zion O, Strenov Y, et al. (2010). MicroRNA expression differentiates between primary lung tumors and metastases to the lung. Pathol Res Pract 206, 578-584.
29. Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, et al. (2009). Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA 106, 1814-1819.
30. Jiang L, Mao P, Song L, Wu J, Huang J, Lin C, Yuan J, Qu L, Cheng SY, and Li J (2010). miR-182 as a prognostic marker for glioma progression and patient survival. Am J Pathol 177, 29-38.
31. Diep CB, Kleivi K, Ribeiro FR, Teixeira MR, Lindgjaerde OC, and Lothe RA (2006). The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes. Genes Chromosomes Cancer 45, 31-41.
32. Midgley R and Kerr D (1999). Colorectal cancer. Lancet 353, 391-399.
33. Juliano R, Alam MR, Dixit V, and Kang H (2008). Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 36, 4158-4171.
34. Huynh C, Segura MF, Gaziel-Sovran A, Menendez S, Darvishian F, Chiriboga L, Levin B, Meruelo D, Osman I, Zavadil J, et al. (2011). Efficient in vivo microRNA targeting of liver metastasis. Oncogene 30, 1481-1488.
35. Luo H, Zhang H, Zhang Z, Zhang X, Ning B, Guo J, Nie N, Liu B, and Wu X (2009). Down-regulated miR-9 and miR-433 in human gastric carcinoma. J Exp Clin Cancer Res 28, 82.
36. Guo LM, Pu Y, Han Z, Liu T, Li YX, Liu M, Li X, and Tang H (2009). MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-κB1. FEBS J 276, 5537-5546.
37. Hu Y, Correa AM, Hoque A, Guan B, Ye F, Huang J, Swisher SG, Wu TT, Ajani JA, and Xu XC (2011). Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer 1, 132-143.
38. Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W, Tamboli P, Wood CG, and Wu X (2010). Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 29, 5724-5728.
39. Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, Prosper F, and Garcia-Foncillas J (2009). Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 125, 2737-2743.
40. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, et al. (2010). miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12, 247-256.
41. Khew-Goodall Y and Goodall GJ (2010). Myc-modulated miR-9 makes more metastases. Nat Cell Biol 12, 209-211.
42. Sun G, Yu RT, Evans RM, and Shi Y (2007). Orphan nuclear receptor TLX recruits histone deacetylases to repress transcription and regulate neural stem cell proliferation. Proc Natl Acad Sci USA 104, 15282-15287.
43. Ormestad M, Astorga J, Landgren H, Wang T, Johansson BR, Miura N, and Carlsson P (2006). Foxf1 and Foxf2 control murine gut development by limiting mesenchymal Wnt signaling and promoting extracellular matrix production. Development 133, 833-843.
44. Danielsen SA, Cekaite L, Ågesen TH, Sveen A, Nesbakken A, Thiis-Evensen E, Skotheim RI, Lind GE, and Lothe RA (2011). Phospholipase C isozymes are deregulated in colorectal cancer-insights gained from gene set enrichment analysis of the transcriptome. PloS One 6, e24419.